A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI2452 (PB2452) With and Without Ticagrelor Pretreatment in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2018
At a glance
- Drugs PB 2452 (Primary)
- Indications Haemorrhage
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors PhaseBio Pharmaceuticals
- 05 Apr 2018 Status changed from planning to recruiting, according to a PhaseBio Pharmaceuticals media release.
- 05 Apr 2018 According to a PhaseBio Pharmaceuticals media release, dosing in the first cohort of subjects in this trial has been completed.
- 30 Nov 2017 New trial record